TNGX
NASDAQTango Therapeutics Inc.
Price$21.42-0.77 (-3.45%)
01:30 PM07:30 PM
News · 26 weeks59-12%
2025-11-022026-04-26
Mix3590d
- Other13(37%)
- Insider10(29%)
- SEC Filings7(20%)
- Analyst3(9%)
- Earnings1(3%)
- Leadership1(3%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Gall Matthew3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- INSIDERNew insider Newcomb Jessica claimed ownership of 67,321 shares (SEC Form 3)3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SECSEC Form DEFA14A filed by Tango Therapeutics Inc.DEFA14A - Tango Therapeutics, Inc. (0001819133) (Filer)
- SECSEC Form DEF 14A filed by Tango Therapeutics Inc.DEF 14A - Tango Therapeutics, Inc. (0001819133) (Filer)
- INSIDERSEC Form 4 filed by Crystal Adam4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SECTango Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
- PRTango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat- Matthew Gall appointed Chief Financial Officer -- Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced key leadership appointments, adding three seasoned industry executives to the Company to support the rapid advancement of vopimetostat, a highly potent and selective PRMT5 inhibitor, towards its first potential regulatory approval in pancreatic cancer. Matthew Gall has been appointed Chief Financial O
- ANALYSTCanaccord Genuity initiated coverage on Tango Therapeutics with a new price targetCanaccord Genuity initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $30.00
- INSIDERSEC Form 4 filed by Crystal Adam4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- ANALYSTCanaccord Genuity initiated coverage on Tango Therapeutics with a new price targetCanaccord Genuity initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $30.00
- INSIDERSEC Form 4 filed by Crystal Adam4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tango Therapeutics Inc.SCHEDULE 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)
- SECSEC Form 144 filed by Tango Therapeutics Inc.144 - Tango Therapeutics, Inc. (0001819133) (Subject)
- PRThe Patent Cliff is Coming, Driving Smart Money Towards Precision OncologyVANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing in the first months of 2026[1], a sign that capital is rotating toward clinical-stage companies with validated science. That capital is not spreading evenly: it is concentrating on precision medicine, where the global oncology precision medicine market is projected to reach $303 billion by 2035[2], growing at approximately 9% annually as targeted cancer treatments move from promising idea to standard care. The five companies in thi
- INSIDERPresident, R&D Crystal Adam sold $303,765 worth of shares (20,251 units at $15.00), decreasing direct ownership by 15% to 112,622 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- PRTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 367,500 shares of its common stock and 60,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The options have an exercise price of $
- SECSEC Form S-8 filed by Tango Therapeutics Inc.S-8 - Tango Therapeutics, Inc. (0001819133) (Filer)
- SECTango Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
- SECSEC Form 10-K filed by Tango Therapeutics Inc.10-K - Tango Therapeutics, Inc. (0001819133) (Filer)
- PRErasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and VopimetostatERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Tango Therapeutics, Inc. (NASDAQ:TNGX, "Tango")) to evaluate Erasca's pan-RAS molecular glue, ERAS-0015, with Tango's PRMT5 inhibitor, vopimetostat (TNG462). "We've disclosed encoura
- PRTango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business HighlightsInitial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the n
- INSIDERPresident, R&D Crystal Adam sold $694,208 worth of shares (54,345 units at $12.77), decreasing direct ownership by 29% to 132,873 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- ANALYSTMizuho initiated coverage on Tango Therapeutics with a new price targetMizuho initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $19.00
- PRTango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor ConferencesBOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call. Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston Corporate presentation on Wednesday, March 4 at 1:10-1:40 PM ETWebcast link here Barclays 28th Annual Global Healthcare Conference, Miami Hosting 1x1 meetings on Tuesday, March 10 2026 Leerink Partners Global Healthcare Conference, Miami Fireside chat
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tango Therapeutics Inc.SCHEDULE 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)
TNGX FAQ
7 questionsWhat does Tango Therapeutics Inc. do?
Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and...Where does TNGX stock trade?
Tango Therapeutics Inc. (TNGX) is listed on NASDAQ.What sector and industry is TNGX in?
Tango Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Tango Therapeutics Inc. go public?
Tango Therapeutics Inc. (TNGX) completed its IPO in 2020.What are analysts saying about TNGX?
Tango Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $3000.00 price target on 2026-04-03. Recent price targets range from $1100.00 to $3000.00.What companies are similar to TNGX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TNGX side-by-side with any of them on Quantisnow.How can I track TNGX on Quantisnow?
Quantisnow aggregates Tango Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TNGX to receive live email and push alerts on every new disclosure.